Indica es e limites da imunoistoquímica no cancer de cabe a e pesco o Indications and pitfalls of immunohistochemistry in head and neck cancer

O estudo imunoistoquímico tem sido empregado para a avalia o do diagnóstico diferencial de neoplasia. OBJETIVO: Avaliar o uso do método nos casos de cancer de cabe a e pesco o. MéTODO: Estudo retrospectivo de casos do Registro Hospitalar de Cancer da institui o. RESULTADOS: De 704 resultados anatomopatológicos, a imunoistoquímica foi realizada em 76 (11%). A maioria correspondeu a carcinomas - 85,80% e, destes, 83,66% eram epidermoides. Todos os exames foram para fins diagnósticos. Houve maior frequência para o uso de 34BE12 (37,18%), AE1/AE3 (35,90%), 35BH11 (28,21%), CD45 (25,64%), CD20 (24,36%), CD30 (24,36%), CK7 (23,08%) e CD3 (23,08%). CONCLUS O: A imunoistoquímica foi usada em 10,67% dos casos de cancer de cabe a e pesco o submetidos a exame anatomopatológico, sendo maior para os carcinomas -- 5,26%. Na determina o do carcinoma epidermoide, seu uso foi de 18,42% do total de neoplasias. Immunohistochemistry (IHC) has been employed in the differential diagnosis of tumors. OBJECTIVE: To assess the use of IHC in cases of head and neck tumor. METHOD: This is a retrospective study of the cases included in the Cancer Registry of the institution. RESULTS: IHC was used in 76 (11%) of 704 pathology tests. Most cases were carcinomas (85.80%), and 83.66% of them were squamous cell carcinomas. All tests were done with diagnostic purposes. The most frequently used antibodies were 34BE12 (37.18%), AE1/AE3 (35.9%), 35BH11 (28.21%), CD45 (25.64%), CD20 (24.36%), CD30 (24.36%), CK7 (23.08%) and CD3 (23.08%). CONCLUSIONS: IHC was used in 10.67% of the head and neck tumor cases submitted to pathology testing, mostly for carcinoma (5.26%). In the determination of squamous cell carcinoma, IHC accounted for 18.42% of all tumors.